Current therapeutic strategies for acute kidney injury

IF 0.9 Q4 UROLOGY & NEPHROLOGY Renal Replacement Therapy Pub Date : 2023-09-18 DOI:10.1186/s41100-023-00502-2
Shigeo Negi, Tatsuya Wada, Naoya Matsumoto, Jun Muratsu, Takashi Shigematsu
{"title":"Current therapeutic strategies for acute kidney injury","authors":"Shigeo Negi, Tatsuya Wada, Naoya Matsumoto, Jun Muratsu, Takashi Shigematsu","doi":"10.1186/s41100-023-00502-2","DOIUrl":null,"url":null,"abstract":"Abstract Acute kidney injury (AKI) is an emerging public health problem worldwide and is associated with high morbidity and mortality. The high mortality rate can be attributed to the lack of pharmacological therapies to prevent and treat AKI. Renal replacement therapy (RRT) plays a pivotal role in the treatment of patients with severe AKI. However, the mortality rate of patients with AKI requiring RRT exceeds 50%. Although studies on RRT for AKI have begun to resolve some of the associated problems, many issues remain to be addressed. Notably, the optimal timing of the initiation of RRT for AKI is still being debated. Recently, new therapeutic strategies for AKI have been developed. Angiotensin II and recombinant alkaline phosphatase treatment are expected to improve the clinical outcomes of patients with distributive and vasodilatory shock. Moreover, mitochondrial-targeted agents have been developed for the treatment of patients with AKI. This review is focused on the optimal timing of RRT for AKI and the new pharmacological interventions and therapies for AKI.","PeriodicalId":21028,"journal":{"name":"Renal Replacement Therapy","volume":"121 1","pages":"0"},"PeriodicalIF":0.9000,"publicationDate":"2023-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Renal Replacement Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s41100-023-00502-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract Acute kidney injury (AKI) is an emerging public health problem worldwide and is associated with high morbidity and mortality. The high mortality rate can be attributed to the lack of pharmacological therapies to prevent and treat AKI. Renal replacement therapy (RRT) plays a pivotal role in the treatment of patients with severe AKI. However, the mortality rate of patients with AKI requiring RRT exceeds 50%. Although studies on RRT for AKI have begun to resolve some of the associated problems, many issues remain to be addressed. Notably, the optimal timing of the initiation of RRT for AKI is still being debated. Recently, new therapeutic strategies for AKI have been developed. Angiotensin II and recombinant alkaline phosphatase treatment are expected to improve the clinical outcomes of patients with distributive and vasodilatory shock. Moreover, mitochondrial-targeted agents have been developed for the treatment of patients with AKI. This review is focused on the optimal timing of RRT for AKI and the new pharmacological interventions and therapies for AKI.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
急性肾损伤的当前治疗策略
急性肾损伤(AKI)是一个新兴的全球公共卫生问题,具有较高的发病率和死亡率。高死亡率可归因于缺乏预防和治疗AKI的药物治疗。肾替代疗法(RRT)在重度AKI患者的治疗中起着关键作用。然而,需要RRT的AKI患者死亡率超过50%。尽管RRT治疗AKI的研究已经开始解决一些相关问题,但仍有许多问题有待解决。值得注意的是,对于AKI开始RRT的最佳时机仍存在争议。最近,AKI的新治疗策略得到了发展。血管紧张素II和重组碱性磷酸酶治疗有望改善分布性和血管扩张性休克患者的临床预后。此外,线粒体靶向药物已被开发用于治疗AKI患者。本文综述了AKI的最佳RRT时机以及AKI的新药物干预和治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Renal Replacement Therapy
Renal Replacement Therapy Medicine-Transplantation
CiteScore
1.70
自引率
8.30%
发文量
57
审稿时长
19 weeks
期刊最新文献
Three cases of mushroom poisoning with an unexpected initial presentation: acute kidney injury with Amanita proxima poisoning A case of progressive multifocal leukoencephalopathy in a post-kidney transplant patient with improvement after discontinuation of immunosuppressive drugs and combination therapy with mefloquine and mirtazapine Diaphragmatic dysfunction in hemodialysis patients: risk factors and effect of incentive spirometry training Utility of the low physical activity questionnaire for hemodialysis patients with frailty: a cross-sectional study Sodium zirconium cyclosilicate hydrate reduces medical expenses compared with hemodialysis in patients with acute hyperkalemia
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1